“Our team at Essential Ingredients is very grateful to DuPont for the opportunity to exclusively represent their collection of enzymes in the U.S and Canada cleaning markets,” said H. Harrison Finney, VP of Sales and Marketing at Essential Ingredients.

WILMINGTON, Del. (PRWEB)
June 29, 2020

DuPont Nutrition & Biosciences (DuPont) and Essential Ingredients have reached an expanded distribution agreement in which Essential Ingredients will be the exclusive distributor for DuPont’s cleaning enzyme solutions in the United States and Canada for the household, industrial and institutional market segment.

“Our team at Essential Ingredients is very grateful to DuPont for the opportunity to exclusively represent their collection of enzymes in the U.S and Canada cleaning markets,” said H. Harrison Finney, VP of Sales and Marketing at Essential Ingredients. “DuPont has been a valued partner of ours since 2015, and we have established a strong relationship through our shared desire to go above and beyond in order to help our customers create the best products possible. We look forward to continuing to delight customers and helping grow the DuPont enzyme business for years to come.”

DuPont’s enzymes offer next generation cleaning for next generation living to customers and end consumers.

“We’re always working to optimize our network of channel partners in the region and are happy to be able to expand our successful partnership with Essential Ingredients,” said Justin Conklin, North America sales leader, DuPont Nutrition & Biosciences. “With help from Essential Ingredients, we’ll be able to provide the best service to our current customers and grow by bringing our innovative products to new customers. Together we can inspire more sustainable, cost-efficient cleaning solutions in the United States and Canada,”.

From the lab to the home, DuPont’s cleaning solutions, including the PREFERENZ® line of laundry enzymes and EXCELLENZ® line of dishwashing enzymes, deliver the sustainable performance customers and end-consumers are demanding.

The OPTIMASE® range provides biological catalysts that deliver industry-leading cleaning performance while allowing for reduced labor and cycle-times, decreasing the impact of harsh chemicals on the wear-and-tear of equipment, and extending the lifetime of linens and fabrics for the industrial & institutional segment.

About Essential Ingredients, Inc.

Essential Ingredients is an international distributor of raw materials used to manufacture personal care, household, and industrial products. In 2017, Forbes magazine recognized the company as one of its Small Giants: America’s Best Small Companies. Essential Ingredients is a 100% employee owned business following the implementation of an Employee Stock Ownership Plan (ESOP) in 2011. The company invests in and depends on its employee owners who in turn care about their company, their customers, and supplier partners they serve. In 2019, Essential Ingredients was awarded Certified Evergreen status by the Tugboat Institute for their dedication to continual improvement and enduring excellence around values, practices, and people. The team at Essential Ingredients is committed to remaining an independent specialty chemical distributor that will prosper for generations to come. More information can be found at http://www.essentialingredients.com

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or http://www.biosciences.dupont.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com.

###

7/29/2020

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Annamarieke Van Heeswijk

+1 585-259-9486

Annemarieke.Van.Heeswijk@dupont.com

Share article on social media or email:

Cancer knows no boundaries, so we are proud to support the hospital’s goal of working to eradicate childhood cancer across the globe.

BURLINGTON, Mass. (PRWEB)
June 29, 2020

Dimensional Insight®, maker of Diver Platform®, the 2020 Best in KLAS healthcare business intelligence/analytics solution, today announced that it is the registration sponsor for the St. Jude Walk/Run Boston for the second straight year on Saturday, Sept. 26, at Boston Common in observance of Childhood Cancer Awareness Month.

“The mission of St. Jude Children’s Research Hospital® is one that we strongly believe in as a company because it helps children everywhere who are referred to St. Jude when there is nothing more their local doctors can do,” says Fred Powers, CEO and co-founder of Dimensional Insight. “Cancer knows no boundaries, so we are proud to support the hospital’s goal of working to eradicate childhood cancer across the globe.”

Based in Memphis, Tenn., St. Jude treats children from across the country, including Boston, and beyond. Treatments invented at St. Jude have helped push the overall cancer survival rate from 20 percent to more than 80 percent since it opened nearly 60 years ago. St. Jude freely shares the discoveries it makes, so every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.

“The work St. Jude is doing today is only possible because of the community’s support, so we are encouraging those who are able to join the fight against childhood cancer,” says Kathy Sucich, director of healthcare marketing at Dimensional Insight and St. Jude Walk/Run Planning Committee member. “Events like this help support the no-bill model at St. Jude, which allow families to focus on helping their child get well and removes any financial worries related to treatment, travel, housing, or food during their stay.”

Please monitor the event webpage for St. Jude Walk/Run Boston updates. To register for a team or make a donation, visit the Dimensional Insight team page.

About Dimensional Insight

Dimensional Insight® is a leading provider of analytics, data management, and performance management solutions, offering a complete portfolio of capabilities ranging from data integration and modeling to sophisticated reporting, analytics, and dashboards. The company is a seven-time Best in KLAS winner in healthcare business intelligence and analytics, most recently ranking #1 in 2020. Founded in 1989, Dimensional Insight has thousands of customer organizations worldwide. Dimensional Insight consistently ranks as a top performing analytics organization by customers and industry analysts in its core market segments including healthcare, manufacturing, and beverage alcohol. For more information, please visit dimins.com.

Share article on social media or email:

The patient and caregiver testimonies gathered by the FSHD Society will be published in a “Voice of the Patient Report” that will be submitted to the FDA, for inclusion in the framework used to evaluate future FSHD therapies.

LEXINGTON, Mass. (PRWEB)
June 29, 2020

The FSHD Society is holding a landmark meeting today in which individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) will tell representatives from the U.S. Food and Drug Administration (FDA) about how the muscle-wasting disease affects their health, and what they hope future treatments will do to improve their quality of life. One of the most common types of muscular dystrophy, FSHD affects an estimated 1 in 8,300 people in the general population. Caused by a genetic aberration on chromosome 4, FSHD results in a life-long, progressive loss of muscle strength, with around 20 to 25 percent of affected individuals needing a wheelchair by age 50. There is currently no treatment to slow or stop the disease.

Today’s meeting, called the “Voice of the Patient Forum,” is an externally led Patient-Focused Drug Development (EL-PFDD) meeting recognized by the FDA. A key component of the Society’s Therapeutic Accelerator initiative, the meeting had originally been scheduled for April 21, 2020, in College Park, Maryland. With the outbreak of COVID-19 this spring, the meeting had to be rescheduled and reformatted as a live webcast to protect participants from potential exposure to the virus. Nearly 500 people have registered for the virtual event. The meeting is co-sponsored by Fulcrum Therapeutics, Muscular Dystrophy Association, and Optum. Friends of FSH Research is participating as well.

The PFDD meetings, started in 2012 by the FDA, are used to obtain patient perspectives on specific diseases and their treatments. The success of these meetings led FDA to set up a mechanism for patient groups to organize “externally led” PFDD meetings.

According to the FDA, “PFDD meetings give FDA and other key stakeholders, including medical product developers, health care providers, federal partners, an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during our review of a marketing application.”

The FSHD Society’s meeting will provide individuals with FSHD, caregivers, and other stakeholders an opportunity to share their experiences and preferences so that the FDA and the biopharmaceutical industry can:

• 
  understand the FSHD patient journey, and recognize patient preferences and risk tolerance so these may be translated into improved clinical trial designs, selection criteria, and development of outcome measures relevant to FSHD drug development;
• demonstrate the complexity and heterogeneity of FSHD, with the end goal of development programs and trial designs that will reflect these aspects of the disease;
• create a practical, scientifically rigorous framework that incorporates patient preferences and patient-reported outcomes into FSHD clinical research to ensure that trials are measuring not only statistical success, but also demonstrating meaningful benefit to individuals with FSHD;
• better understand patient and caregiver perceptions about the treatments they are currently using, which treatments are most beneficial, and which ones may have side effects;
• encourage identification and use of approaches and best practices to facilitate patient enrollment and minimize the burden of patient participation in clinical trials; and
• ensure that people with FSHD understand the value of their participation in clinical trials, and how their input impacts FDA and biopharmaceutical industry decision-making and outcomes at all levels to both improve their own health-related quality of life as well as that of others with FSHD, now and in the future.

Prior to the meeting, the FSHD Society distributed online surveys related to the disease burden and unmet medical need of FSHD and received nearly 2,500 responses. “Data from these surveys was used to plan our Voice of the Patient Forum and will also be included in our report to the FDA,” said June Kinoshita, Director of Research and Patient Engagement at the FSHD Society.

Individuals and family members living with FSHD will be able to submit written testimonies if they are unable to participate in today’s live webcast. Submissions will be accepted until July 31 and can be sent to comments@fshdsociety.org, said Kinoshita.

The patient and caregiver testimonies gathered by the FSHD Society will be published in a “Voice of the Patient Report” that will be submitted to the FDA, for inclusion in the framework used to evaluate future FSHD therapies.

About the FSHD Society

The FSHD Society is the world’s largest research-focused patient organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy. The Society has catalyzed major advancements and is accelerating the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. The FSHD Society has transformed the landscape for FSHD research and is committed to making sure that no one faces this disease alone. The Society offers a community of support, news, and information through its website at https://www.fshdsociety.org.

Share article on social media or email:

Returning to Work During the COVID-19 Pandemic

Mastery Training Services now offers a selection of training on COVID-19 as well as on back to work safety procedures, including social distancing, the use of face coverings and other PPE, and cleaning and sanitization procedures.

NOVI, Mich. (PRWEB)
June 29, 2020

As many states are in the midst of returning to work employers are required to train employees on COVID-19, as well as on the new safety procedures in place to help prevent the spread of disease. To aid employers in this effort, Mastery Training Services has released a new selection of courses on going back to work during the coronavirus pandemic.

State and federal recommendations require employers to provide COVID-19 training as they return to work. For example, in the state of Michigan per Executive Order No. 2020-114, “employers must provide training that covers, at a minimum, workplace infection-control practices, the proper use of personal protective equipment (PPE), steps the employee must take to notify the business or operation of any symptoms of COVID-19 or a suspected or confirmed diagnosis of COVID-19, and how to report unsafe working conditions.”

Mastery Training Services now offers a selection of training on COVID-19 as well as on back to work safety procedures, including social distancing, the use of face coverings and other PPE, and cleaning and sanitization procedures. The current available list of courses includes:

Employers should review their own local training requirements to determine if additional content is needed based on location and industry of the operation.

These courses are available for purchase on a single play, pay-per-view basis on mastery.com or as part of a licensed library at an employer rate.

These courses are also available in Mastery Training Services’ library of over 1,600 online training courses. All of Mastery Training Services’ VOD courses are published on the MasteryTCN™ courseware platform, which provides continuity in the learner experience from one course to the next. All courses on the platform play across all devices and browsers, giving users the ultimate flexibility for when and where they can access training assignments.

Mastery Training Services’ library covers a variety of topics for organizations of all sizes, across industries. If you are looking to train your workforce, click here.

About Mastery Training Services

Mastery Training Services is a leader in the corporate online training marketplace. We help organizations grow and become more successful with our comprehensive workplace training systems and services. In this way, Mastery fulfills its mission of helping build more successful, effective, and amazing organizations.

Share article on social media or email:

Logo

“Our doctors fulfill their purpose by being totally accountable for helping their patients achieve better health.”

MIAMI (PRWEB)
June 29, 2020

ChenMed, the nation’s leading senior-focused primary care practice, today announced that doors are opening on 15 new Dedicated Senior Medical Centers during the next 20 weeks, advancing the company’s 35-year tradition of transforming care of the neediest populations.

This 25.7% expansion of ChenMed practices located in underserved communities means tens of thousands of low-income seniors in Cincinnati, Cleveland, Memphis, Orlando, Philadelphia and St. Louis will, at convenient and beautiful locations in their neighborhoods, be able to start accessing highly personalized primary care that delivers better health.

“Our commitment to underserved communities has never been stronger,” explains Christopher Chen, M.D. ChenMed CEO. “Given recent events and the calls for more social and racial justice, there couldn’t be a better time to be approaching 80 primary care centers in 10 states. Despite the COVID-19 pandemic, we are unwavering in our intention to continue to deliver on our mission by giving underserved seniors the same concierge care that is available to Americans with greater financial means.”

Dr. Chen adds: “Our doctors fulfill their purpose by being totally accountable for helping their patients achieve better health. Plus, ChenMed centers offer services that help reduce barriers to healthy living, from transportation assistance to on-site medications to helping with social services.”

Three new Dedicated centers in St. Louis, and a new, fifth Dedicated center in Philadelphia will start seeing patients July 1, 2020. Then, in rapid succession, Dedicated will open doors on the first of three new Cleveland centers July 20; the first of three new Cincinnati centers August 31; the first of three new Memphis centers, plus the first of two Orlando centers September 28. All 15 new Dedicated centers are expected to be seeing patients by November 9.

Unlike many fee-for-service healthcare providers that were slow to adapt approach to care as they became aware of the coronavirus pandemic, ChenMed, as a global-risk provider of choice for more than 20 Medicare Advantage health plans, has remained flexible, fast, and focused in helping protect both patients and employees from COVID-19 risks:

• 
  Flexible … ChenMed established a coronavirus task force and decided to shift patient care focus to helping at-risk seniors stay healthy, happy and home. In Jan. 2020, ChenMed moved all data, including access to its proprietary EHR system, to the secured cloud. This enables thousands of employees, including all doctors and care team members, to effectively work remotely.
• Fast … Weeks before most communities initiated formal shelter-at-home orders, ChenMed successfully pivoted from 98% in-center patient appointments to 95% virtual appointments in just one week – all while keeping medical centers open so patients in need of urgent in-person care had an option beyond the emergency room. Then, as patient needs for safe in-person primary care visits rose over time, ChenMed adapted again.
• Focused … ChenMed primary care doctors intentionally have the industry’s smallest patient panels and are financially rewarded for delivering VIP service and better health outcomes. They see patients virtually or in-person as often as needed, and they do whatever it takes to help their patients thrive.

The ethnically diverse, low-income, and generally frail seniors ChenMed serves benefit greatly from the practice’s proven ability to pivot whenever needed to improve both quality of care and patient experience. For years, ChenMed primary care physicians have been giving their cell phone numbers to patients asking them to text or call whenever a health concern arises.

Plus, ChenMed doctors and care team members consistently encourage same-day in-person appointments whenever needed at convenient neighborhood locations. The Chen, Dedicated, and JenCare Senior Medical Centers offer door-to-doctor transportation. They also find ways to stay open — as safe, secure and welcoming care environments — even when communities are impacted by extreme weather, coronavirus stay-at-home orders, or periods of civil unrest.

“Our primary care doctors serve an average of just 400 patients each,” says Gaurov Dayal, M.D., ChenMed President New Markets and Chief Growth Officer. That’s less than one-fifth the national average of 2,300 patients per primary doctor, and it is a real quality of care advantage for our seniors – especially for those with multiple chronic health challenges.”

Noting how ChenMed doctors average 10 times more face-to-face time with patients than a typical physician does, Dr. Dayal reinforces how vital physician time investment is. He reports the average age ChenMed patients is 72 years; that 75 percent of ChenMed patients are living with five or more major and chronic health conditions; that 95 percent of ChenMed patients are low-income (within 300 percent of U.S. poverty level); and 75 percent of ChenMed patients are minorities (50 percent African American) who have increased health risks year-round, heightened by the coronavirus pandemic.

Aligned incentives fuel better health outcomes and ChenMed growth

“The future is bright for the value-based care that ChenMed doctors provide,” says Dr. Chen, “and we’ve been seeing a record number of outstanding primary care doctors applying to join us during the coronavirus pandemic.”

He adds this news is not surprising, because “our doctors have the freedom to do what’s needed by patients, and not to be distracted by concerns about what services will be covered by Medicare.” Dr. Chen then spotlights ChenMed’s five-fold increase in first and second quarter new physician signings achieved in 2020; and the high levels of satisfaction both ChenMed doctors and patients have precisely because they are focused on improving health outcomes together.

“We are absolutely bullish about our new market openings,” says Dr. Dayal, “and expect our presence will grow dramatically in Cincinnati, Cleveland, Memphis, Orlando and St. Louis, just like we are doing in the Philadelphia market we continue to grow.” During the year ending June 30, 2019, Dedicated Senior Medical Center membership growth in Philadelphia exceeded 62 percent.

About ChenMed

For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. ChenMed is a privately owned medical, management and technology company that currently operates 59 primary care medical practices for diverse populations of seniors. A provider of choice for some 20 Medicare Advantage health insurance plans, ChenMed brands include Chen Senior Medical Center, Dedicated Senior Medical Center, and JenCare Senior Medical Center.

Results of ChenMed’s high-touch approach to primary care are impressive, as illustrated in the Modern Healthcare cover story, which reports, “Indeed, ChenMed’s approach has resulted in 50 percent fewer hospital admissions compared with a standard primary-care practice, 28 percent lower per-member costs and significantly higher use of evidence-based medications.” Learn more about the high-growth company, where patients also average 75 percent fewer emergency room visits @ http://www.ChenMed.com, and/or follow us @chenmed.

Stem Cell Therapy for Liver Failure in Mexico (888) 988-0515

Effective stem cell treatment for liver failure requires a large amount of stem cells. R3 offers those numbers of cells in Mexico with options that are safe and cost effective!

SAN DIEGO (PRWEB)
June 29, 2020

R3 International is now offering a new program for stem cell therapy for liver failure in Mexico. The program offers up to 200 million stem cells, with the cost starting at only $8975.

Millions of individuals suffer from chronic liver disease, which occurs due to a number of causes such as hepatitis, cirrhosis, metabolic diseases, and other conditions. All too often, conventional therapies fail to provide the desired result.

Stem cell therapy has been shown in several studies to produce beneficial results for liver failure. This includes a study of 43 patients from 2012 in Stem Cells and Translational Medicine noting significant increase in survival rates, along with no adverse events.

In its new program, R3 International uses the same weight based protocol. Each treatment provides up to 50 million stem cells at a time, with the treatment occurring at the stem cell therapy clinic in Tijuana Mexico. To date, hundreds of patients have received stem cell therapy in Mexico with R3 for a variety of conditions. No adverse events have been reported, and outcomes have been sensational for organ failure, arthritis, diabetes, dementia, stroke, stem cells for Lyme disease, Crohns and many more.

In order to receive treatment, patients start with a free phone consultation with the licensed, experienced stem cell doctor from R3 International. After the consult and review of medical records, the doctor provides a treatment recommendation. Then the dedicated patient concierge representative will assist with travel logistics and transportation from San Diego to the clinic is provided.

Simply call (888) 988-0515 to schedule the phone consultation and learn about options for treatment.

Share article on social media or email: